BioSpace News Archive

ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2023 on Thursday, January 26, 2023, after the New York Stock Exchange closes.

Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced that the first patient was dosed with Debio 4126, a 3-month extended-release formulation of octreotide, in their open-label, non-randomized, single-arm, multicenter phase 1b study (Debio 4126-102).

Every time a serious new COVID-19 virus variant emerges, Gilead virologists Charlotte Hedskog and John Bilello, alongside their teams, mobilize as so-called “variant hunters.”

The Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals in Cleveland have granted an ADDF-Harrington Scholar Award to Christiane Wrann, PhD, DVM, Associate Professor in Medicine at the Cardiovascular Research Center and the McCance Center for Brain Health at Massachusetts General Hospital and the Harvard Medical School in Boston.

Senda Biosciences, Inc., a company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Luke O’Neill, Ph.D., as Chief Scientific Officer.

Capricor Therapeutics announced today the publication of a preclinical study highlighting new advances for its engineered exosome program.

The American Academy of Pediatrics (AAP), the Pediatric Endocrine Society (PES) and the American Thyroid Association (ATA) have published new guidelines for the treatment of congenital hypothyroidism (CH).

Today, the American Cancer Society (ACS) released Cancer Statistics, 2023, the organization’s annual report on cancer facts and trends. According to the report, overall cancer mortality has dropped 33% since 1991, averting an estimated 3.8 million cancer deaths.

Medical technology company Gradient Health today announced a landmark collaboration with not-for-profit health system Cone Health, helping to accelerate innovation of medical imaging technologies.

LinusBio , a leader in precision exposome sequencing, today announced it raised over $16 million in Series A funding to deliver a novel platform that bridges genomics, the environment, and biological response.